Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Hidden Severe Asthma in Primary Care versus ISAR Cohort Professor David Price 20/02/2020
Finalised An observational evaluation of prescribing of fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist (ICS/LABA): fluticasone propionate / formoterol (FP/FOR) and adverse events in routine primary care at 18-months and 36-months post launch Miss Jessica Martin 10/10/2019
Finalised COMPARABILITY OF POPULATION DEFINITIONS WITHIN & BETWEEN GLOBAL DATABASES – DEVELOPING TOOLS FOR OBSERVATIONAL RESEARCH Dr Jerry Krishnan 20/08/2019
Finalised Effectiveness of Dymista® in patients with allergic rhinitis and asthma Professor David Price 13/08/2019
Finalised Characterising Patient Pathways to the Diagnosis of Idiopathic Pulmonary Fibrosis: Real World Data Study Professor David Price 20/06/2019
Finalised IDENTIFYING OPPORTUNITIES FOR EARLIER DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS IN ROUTINE CARE IN THE UK: A RETROSPECTIVE CLINICAL COHORT STUDY Professor Richeldi Luca 12/03/2019
Finalised Use of degarelix among patients with prostate cancer in daily practice Professor David Price 28/02/2019
Finalised Randomised Controlled Trial (RCT) vs Real Life initiative Professor David Price 18/02/2019
Finalised Real-life effectiveness evaluation of asthma treatment in Korea Professor David Price 24/01/2019
Finalised Historical matched-cohort study assessing whether the use of inhaled corticosteroids shortens time to first diagnosis or accelerates the progression of side effects compared to non-ICS therapies in patients with Chronic Obstructive Pulmonary Disease. Professor David Price 16/01/2019
Finalised CRITIKAL Study Professor David Price 16/01/2019
Finalised Characteristics of asthma patients at risk of failed Diskus use in primary care: a retrospective cohort study Professor David Price 16/01/2019
Finalised Dose response curves for patients prescribed small & large particle ICS formulation: an observational evaluation of the comparative effect of ICS dose on asthma control achieved in real-life UK patients managed on extrafine hydrofluoroalkane beclomethasone, ciclesonide, fluticasone propionate, or Clenil Professor David Price 16/01/2019
Finalised An observational evaluation of the off-label prescribing and safety of glycopyrronium bromide for symptomatic treatment of severe sialorrhoea (drooling) and/or hyperhidrosis (excessive sweating) Professor David Price 21/12/2018
Finalised An observational historical cohort study to evaluate chronic disease onset associated with long-term oral corticosteroid and it’s cost impact on patients in the OPCRD / CPRD databases Professor David Price 19/12/2018
Finalised Evaluation of the undertreatment and disease outcomes for patients with coexisting Heart Failure and Chronic Obstructive Pulmonary Disease Miss Jessica Martin 19/12/2018
Finalised Underuse of beta-blockers in patients with heart failure and COPD Miss Jessica Martin 19/12/2018
Finalised Studying the value of fractional exhaled Nitric Oxide and blood eosinophils as biomarkers in predicting which patients will suffer from more frequent asthma exacerbations, and evaluating the subsequent healthcare resource utilisation Professor David Price 07/11/2018
Finalised Asthma management in France and the United Kingdom Dr David Van Ganse 29/10/2018
Finalised Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 2) Professor David Price 23/10/2018
Finalised COMPARATIVE EFFECTIVENESS AND SAFETY OF BUDESONIDE STERINEBS® VS. PULMICORT RESPULES® IN A US POPULATION OF ASTHMA PATIENTS. Professor David Price 23/10/2018
Finalised Characterising patients and examining real-life outcomes for UK patients with COPD initiating on or changing to Fostair Professor David Price 23/10/2018
Finalised The role of adherence to inhaled corticosteroids in the relationship between blood eosinophilia and asthma control Dr Bakhtiyor Khalikulov 23/10/2018
Finalised Investigating the possible role of BLood eosinophil counts in guiding ANti-inflammatory treatment of COPD exAcerbations (BLANCA) Professor David Price 17/10/2018
Finalised Real-world effectiveness of extra-fine Ciclesonide (Alvesco®) versus standard particle inhaled corticosteroid (ICS) Professor David Price 10/10/2018
Finalised Real-life effectiveness evaluation of asthma treatment in Korea Professor David Price 11/07/2017
Finalised Does the cost of inhaler devices affect therapy adherence and disease outcomes? Professor David Price 26/01/2017
Finalised Real-life effectiveness evaluation of budesonide/formoterol (BF) Spiromax for the management of asthma and COPD Dr Jaco Voorham 16/01/2017
Finalised Incidence of oral thrush in COPD patients prescribed ICS as part of ICS/LABA therapy Miss Lucy Wood 12/07/2016
Finalised Real life effectiveness and cost impact evaluation of fixed dose combination fluticasone propionate/formoterol (Flutiform®) compared to fluticasone propionate/salmeterol (Seretide®) Professor David Price 02/03/2016
Ongoing ADDITION OF ANTIBIOTICS TO USUAL CARE MANAGEMENT OF ASTHMA EXACERBATIONS: A REAL-LIFE COMPARATIVE EFFECTIVENESS STUDY Professor Nikolaos Papadopoulos 18/03/2020
Ongoing Severe Asthma Super-Responders Delphi Exercise Professor John Upham 23/12/2019
Ongoing Longitudinal systemic corticosteroid utilization in the UK, 1990-2018 Professor David Price 07/10/2019
Ongoing The use of a spacer in the delivery of large (Fluticasone Propionate) and small particle (Qvar®) inhaled corticosteroid (ICS) in asthma Professor David Price 24/01/2019
Ongoing Comparative effectiveness and safety of Salbutamol Sterinebs® vs Ventolin Nebules® in COPD patients. Professor David Price 23/10/2018
Ongoing Real-world effectiveness of extra-fine formulations in Denmark Professor David Price 23/10/2018
Ongoing Comparative Effectiveness of Extra-Fine Particle Inhaled Corticosteroid (ICS) and Alternative Guideline-Recommended Step-Up Options in Pre-School Children Professor David Price 10/10/2018
Ongoing Asthma and Type 2 Comorbidities - Real-life Characterisation of Patients with Active Asthma and Type 2 Asthma Comorbidities Professor David Price 09/08/2018
Ongoing Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO) Professor David Price 14/07/2017
Ongoing Effectiveness of triple therapy vs. dual bronchodilation in COPD Professor David Price 30/05/2017
Ongoing ICARUS: Inhaled Corticosteroid And Real life Unlicensed Spacer use – stage 2 Professor David Price 13/02/2017
Ongoing Burden of disease in patients with COPD and high blood eosinophil counts Professor David Price 31/01/2017
Ongoing Burden of severe uncontrolled eosinophilic asthma in the UK population Professor David Price 15/03/2016
Planned An observational cohort study to describe intermittent OCS utilisation and its association with adverse outcomes and healthcare resource use and costs in asthma using the OPCRD and CPRD databases. Professor David Price 04/09/2020
Planned Burden and consequences of the use of COPD-related systemic corticosteroids Professor David Price 24/06/2020
Planned Burden and consequences of the use of COPD-related systemic corticosteroids Professor David Price 23/06/2020
Planned Comparative safety of extrafine beclometasone fixed dose combinations (FDC) and fluticasone FDC in COPD Professor David Price 25/05/2020
Planned A pragmatic, cluster randomized trial evaluating the impact of an enhanced adherence package (dual bronchodilator+add-on+app) on time to treatment failure and other clinical outcomes in exacerbating COPD patients with poor adherence to mono or dual therapy over one year Professor Rupert Jones 31/03/2020
Planned Impact of Optimum Patient Care’s clinical review service Professor David Price 04/02/2020
Planned The burden of rhinitis in Australia Professor David Price 24/01/2019
Planned Training requirements to master inhaler devices available in real-life clinical practice Miss Lucy Wood 06/03/2017
Planned Benefits of high dose ICS in patients with asthma and high blood eosinophil counts Professor David Price 18/10/2016
Planned Inhaled Corticosteroid and Real Life unlicensed Spacer Use (stage 1) Professor David Price 18/04/2016